PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension
- PMID: 1390487
- PMCID: PMC504230
- DOI: 10.1136/bjo.76.4.214
PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension
Abstract
PhXA34, a prostaglandin analogue, was given topically to 40 patients with untreated ocular hypertension in a double masked randomised study. One single dose of 0.3, 1, 3, 10 micrograms, or placebo (vehicle) was given to one eye of each patient. A dose related IOP reduction ranging from 11 to 35% was observed with a maximal effect with 3 and 10 micrograms PhXA34. No hyperaemia was seen except after 10 micrograms PhXA34, where a mild to moderate hyperaemia was seen from 8 hours with a duration of up to 24 hours. Mild foreign body sensation in the PhXA34-treated eye was noted by three patients. No cells or flare were seen.
Similar articles
-
Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.Drugs Aging. 1996 Nov;9(5):363-78. doi: 10.2165/00002512-199609050-00007. Drugs Aging. 1996. PMID: 8922563 Review.
-
Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension.Arch Ophthalmol. 1992 Dec;110(12):1733-8. doi: 10.1001/archopht.1992.01080240073034. Arch Ophthalmol. 1992. PMID: 1463414 Clinical Trial.
-
Latanoprost : an update of its use in glaucoma and ocular hypertension.Drugs Aging. 2003;20(8):597-630. doi: 10.2165/00002512-200320080-00005. Drugs Aging. 2003. PMID: 12795627 Review.
-
PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers.Arch Ophthalmol. 1991 Nov;109(11):1564-8. doi: 10.1001/archopht.1991.01080110100045. Arch Ophthalmol. 1991. PMID: 1755739 Clinical Trial.
-
A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.Clin Ther. 2006 Mar;28(3):332-9. doi: 10.1016/j.clinthera.2006.03.001. Clin Ther. 2006. PMID: 16750448 Clinical Trial.
Cited by
-
Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.Br J Ophthalmol. 1995 Jan;79(1):12-6. doi: 10.1136/bjo.79.1.12. Br J Ophthalmol. 1995. PMID: 7880782 Free PMC article. Clinical Trial.
-
Animal model for uveitic glaucoma.Graefes Arch Clin Exp Ophthalmol. 1994 Sep;232(9):553-60. doi: 10.1007/BF00181999. Graefes Arch Clin Exp Ophthalmol. 1994. PMID: 7959095
-
Prostaglandin analogues in the treatment of glaucoma.Drugs Aging. 1999 May;14(5):387-98. doi: 10.2165/00002512-199914050-00006. Drugs Aging. 1999. PMID: 10408738 Review.
-
Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension.Drugs Aging. 1996 Nov;9(5):363-78. doi: 10.2165/00002512-199609050-00007. Drugs Aging. 1996. PMID: 8922563 Review.
-
Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure.Br J Ophthalmol. 1994 Dec;78(12):899-902. doi: 10.1136/bjo.78.12.899. Br J Ophthalmol. 1994. PMID: 7819171 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous